CNS Pharmaceuticals, Inc.
CNSP
$6.66
$0.152.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.06M | 1.24M | 1.09M | 1.70M | 1.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.25M | 2.41M | 4.34M | 3.20M | 5.63M |
| Operating Income | -3.25M | -2.41M | -4.34M | -3.20M | -5.63M |
| Income Before Tax | -3.22M | -2.38M | -4.30M | -3.18M | -5.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.22M | -2.38M | -4.30M | -3.18M | -5.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.22M | -2.38M | -4.30M | -3.18M | -5.61M |
| EBIT | -3.25M | -2.41M | -4.34M | -3.20M | -5.63M |
| EBITDA | -3.25M | -2.41M | -4.34M | -3.20M | -5.63M |
| EPS Basic | -5.76 | -6.42 | -18.93 | -35.49 | -153.20 |
| Normalized Basic EPS | -3.60 | -4.01 | -11.83 | -22.18 | -95.75 |
| EPS Diluted | -5.76 | -6.42 | -18.96 | -35.55 | -153.20 |
| Normalized Diluted EPS | -3.60 | -4.01 | -11.83 | -22.18 | -95.75 |
| Average Basic Shares Outstanding | 558.90K | 370.10K | 227.20K | 89.50K | 36.60K |
| Average Diluted Shares Outstanding | 558.90K | 370.10K | 227.20K | 89.50K | 36.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |